Benefits
Leg comfort and healthy vein tone (studied in venous insufficiency)
A multi-center, double-blind, placebo-controlled RCT in 166 women with chronic venous insufficiency (CEAP 3-4) given Ruscus extract or placebo for 12 weeks found significant differences favoring Ruscus for: leg volume changes (AUB0-12 of -827 mL × day), leg volume reduction (-16.5 mL at 8 weeks, -20.5 mL at 12 weeks), ankle and leg circumference, and subjective symptoms (heavy/tired legs, sensation of tension). A foundational Western RCT reporting improved leg comfort and reduced leg-volume measures in this population.
Everyday leg comfort: heaviness, tiredness, tension
In studies of people with venous insufficiency, Ruscus was associated with improvements in leg heaviness, sensation of tension, tingling, leg discomfort, and evening swelling. Quality of life measures also improve. Effect typically observed within 4-8 weeks of consistent dosing. May support everyday leg comfort in people looking to maintain healthy circulation; not a substitute for medical care of any diagnosed vein condition.
Traditional use for rectal vein comfort
Hemorrhoids are essentially varicose veins of the rectum — same vascular mechanism. Ruscus has long been used traditionally for hemorrhoids; venoactive mechanism plausibly applies. Limited modern RCT evidence specifically for hemorrhoids but mechanistic basis strong. Sometimes included in traditional vein-comfort formulas.
Arm-volume measures studied after breast cancer surgery (combination product — reported for context)
A Ruscus + hesperidin + vitamin C combination has been studied for upper extremity lymphedema after breast cancer surgery, showing reduction in arm volume in some trials. This is combination-product research reported for completeness; it is not a claim that the herb treats lymphedema, and evidence is limited to the combination formula.
Blood-pressure regulation on standing (preliminary, mechanism-based)
Its mild vasoconstrictive activity (alpha-adrenergic agonism) offers a mechanistic rationale for supporting healthy blood pressure on standing. Human efficacy evidence is very limited; this is a preliminary, mechanism-based rationale only. Different mechanism from CVI applications (vasoconstriction vs venous tone).
Mechanism of action
Alpha-adrenergic agonism — direct venous tone enhancement
Ruscogenins have alpha-1 adrenergic agonist activity, producing direct vasoconstriction of venous smooth muscle and increased venous tone. This is the primary mechanism behind its effect on leg comfort — it supports healthy venous tone, relevant to the pooling and heaviness associated with weak vein tone. Distinct from typical 'flavonoid-class' venoactive mechanisms.
Anti-elastase and anti-hyaluronidase activity
Saponins inhibit elastase and hyaluronidase enzymes that degrade venous wall connective tissue. Protects against progressive venous wall weakening and capillary fragility — relevant to maintaining long-term venous wall integrity beyond immediate leg comfort.
Capillary permeability reduction
Ruscus reduces capillary permeability and microvascular leakage — addressing the edema component of CVI directly. Combined with venous tone effects, produces multi-mechanism benefit on the integrated venous-microcirculatory pathology of chronic venous insufficiency.
Anti-inflammatory effects on vessel wall
Saponins reduce inflammation in vessel wall and surrounding tissue — relevant to chronic vein-related inflammation. Supports anti-edema and pain-reduction effects observed clinically.
Clinical trials
Multi-center, double-blind, randomized, placebo-controlled trial (Vanscheidt W, Jost V, Wolna P, Lücker PW, Müller A, Theurer C, Patz B, Grützner KI 2002, Arzneimittelforschung 52(4):243-250, doi:10.1055/s-0031-1299887).
166 women with chronic venous insufficiency (Widmer grade I and II, CEAP 3-4), mean disease duration 14.6-15.1 years. Randomized to Fagorutin Ruscus Kapseln or placebo for 12 weeks. ITT analysis n=148. Primary endpoint: AUB0-12 (area under baseline of leg volume changes over 12 weeks).
Significant differences favoring Ruscus: AUB0-12 -827 mL × day, leg volume -16.5 mL at 8 weeks and -20.5 mL at 12 weeks (p<0.05), significant ankle/leg circumference reduction, significant improvement in heavy/tired legs and sensation of tension symptoms at week 12. Tolerability good/very good in both groups. Authors concluded Ruscus extract effective and well-tolerated for CVI treatment over 3 months. Foundational Western clinical trial validating long traditional use.
Open-label, randomized, multicenter study (Beltramino R, Penenory A, Buceta AM 2000, Angiology 51(7):535-544).
Patients with chronic venous lymphatic insufficiency randomized to Cyclo 3 Fort (Ruscus + hesperidin methylchalcone + ascorbic acid) vs hydroxyethyl rutoside.
Cyclo 3 Fort showed comparable efficacy to hydroxyethyl rutoside for chronic venous lymphatic insufficiency symptoms. Demonstrates Ruscus combination product equivalence to established venoactive comparator. Limited by open-label design but provides supportive evidence in real-world clinical context.
Cluzan RV, Alliotl F, Ghabboun S et al. — Treatment of lymphedema of the upper arm after previous treatment for breast cancer.
Patients with upper arm lymphedema following breast cancer treatment given Cyclo 3 Fort (Ruscus combination).
Reduction in arm volume and lymphedema symptoms. Provides supporting evidence for broader lymphatic/venoactive applications beyond lower limb CVI. Limited rigorous trial methodology by modern standards but adds context to therapeutic profile.